Rilimogene Galvacirepvec

**Semantic type:** Immunologic Factor|Pharmacologic Substance|Virus

**Definition:** A vaccine formulation consisting of recombinant vaccinia virus encoding prostate specific antigen (PSA) and recombinant vaccinia virus encoding three co-stimulatory molecule transgenes B7.1, ICAM-1, and LFA-3 (TRICOM). Vaccination with PSA in combination with TRICOM may enhance antigen presentation, resulting in the augmentation of a cytotoxic T cell (CTL) immune response against tumor cells expressing PSA.

**Synonyms:** - PROSTVAC - Prostvac-V - RILIMOGENE GALVACIREPVEC - Recombinant Vaccinia-PSA(L155)-TRICOM Vaccine - Recombinant Vaccinia-PSA(L155)/TRICOM - Recombinant Vaccinia-PSA(L155)/TRICOM Vaccine - rVaccinia-PSA(L155)-TRICOM Vaccine - rVaccinia-Prostate-Specific Antigen/TRICOM Vaccine